A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.
Headaches associated with menstruation are often resistant to abortive and preventative medications. We performed an open-label study in 20 female migraineurs, employing oral sumatriptan perimenstrually as short-term prophylaxis of menstrual migraine. In 126 sumatriptan-treated cycles, headache was absent in 52.4% and reduced in severity by 50% or greater in 42%. Breakthrough headaches were rare and significantly reduced in severity compared with baseline headaches.
Newman
L C
LC
Department of Neurology, The Albert Einstein College of Medicine, Montefiore Headache Unit, Bronx, NY 10467, USA.
Lipton
R B
RB
Lay
C L
CL
Solomon
S
S
D000328:Adult; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D010865:Pilot Projects; D018170:Sumatriptan / Q000008:administration & dosage*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
D014662:Vasoconstrictor Agents; D018170:Sumatriptan